Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Predictive Oncology ( (POAI) ) has issued an announcement.
On July 8, 2025, Predictive Oncology received a notification from Nasdaq indicating non-compliance with the minimum bid price requirement, as its stock price had closed below $1.00 for 30 consecutive business days. The company has until January 5, 2026, to regain compliance by achieving a stock price of at least $1.00 for 10 consecutive days. Failure to comply may result in delisting, though the company may be eligible for additional time if it meets other listing standards. Predictive Oncology is actively monitoring its stock price and considering options to address the issue.
The most recent analyst rating on (POAI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Predictive Oncology stock, see the POAI Stock Forecast page.
Spark’s Take on POAI Stock
According to Spark, TipRanks’ AI Analyst, POAI is a Neutral.
The overall stock score is heavily impacted by poor financial performance and valuation metrics. The technical analysis also indicates bearish momentum. Regulatory challenges and the potential for Nasdaq delisting exacerbate the company’s risk profile.
To see Spark’s full report on POAI stock, click here.
More about Predictive Oncology
Average Trading Volume: 164,856
Technical Sentiment Signal: Strong Sell
Current Market Cap: $7.69M
Learn more about POAI stock on TipRanks’ Stock Analysis page.